Manuel Botana (Manuel Botana López)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Left Ventricular

Top Venues

Advances in therapy

Diabetes therapy : research, treatment and education of diabetes and related disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Manuel Botana, Francisco Javier Escalada San Martín, Agustín Ángel Merchante Alfaro, Rebeca Reyes, Pedro Rozas
Prevention of Cardiorenal Complications with Sodium-Glucose Cotransporter Type 2 Inhibitors: A Narrative Review. Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (Suppl 1) (2022)